Absci Corporation (ABSI)
2.90
0.19 (7.01%)
At close: Jan 15, 2025, 1:48 PM
undefined% (undefined)
| Bid | 2.89 |
| Market Cap | 332.99M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.93 |
| PE Ratio (ttm) | -3.12 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 2.9 |
| Volume | 2,963,166 |
| Avg. Volume (20D) | 2,956,378 |
| Open | 2.84 |
| Previous Close | 2.71 |
| Day's Range | 2.65 - 2.90 |
| 52-Week Range | 2.45 - 6.72 |
| Beta | undefined |
About ABSI
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington....
Industry Biotechnology
Sector Healthcare
IPO Date Jul 22, 2021
Employees 155
Stock Exchange NASDAQ
Ticker Symbol ABSI
Website https://www.absci.com
Analyst Forecast
According to 6 analyst ratings, the average rating for ABSI stock is "Buy." The 12-month stock price forecast is $8, which is an increase of 175.94% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Absci Corporation is scheduled to release its earnings on Mar 20, 2025,
before market opens.
Analysts project revenue of $1.82M, reflecting a 438.46% YoY growth and earnings per share of -0.21, making a -16.00% decrease YoY.
Analysts project revenue of $1.82M, reflecting a 438.46% YoY growth and earnings per share of -0.21, making a -16.00% decrease YoY.
6 days ago ·
Source
+4.89%
Abscri shares are trading higher after the company...
Unlock content with
Pro Subscription
1 week ago ·
Source
+3.37%
Absci shares are trading higher after the company announced a partnership with Invetx to bring a generative AI drug creation platform to animal health.
